Acticor Biotech
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
ALACT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012519668 (+1 more)
- LEI:
- 969500K433EK1G89EV95
- Country:
- France
- Address:
- 82 AVENUE DU MAINE, 75014 PARIS
- Website:
- https://www.acticor-biotech.com
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Acticor Biotech is a clinical-stage biopharmaceutical company, established as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on cardiovascular emergencies like acute ischemic stroke. Its lead product candidate, glenzocimab, is a 'first-in-class' drug designed to safely treat the acute phase of thrombotic events. Acticor Biotech has also explored the use of glenzocimab in other indications, such as acute respiratory distress syndrome (ARDS).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-06 08:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 171.0 KB | ||
| 2025-01-06 08:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 169.3 KB | ||
| 2024-12-19 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 205.7 KB | ||
| 2024-12-19 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.6 KB | ||
| 2024-12-10 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 202.1 KB | ||
| 2024-12-10 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 214.1 KB | ||
| 2024-11-06 08:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 177.1 KB | ||
| 2024-11-06 08:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 179.2 KB | ||
| 2024-11-04 11:46 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 322.8 KB | ||
| 2024-11-04 11:46 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 311.2 KB | ||
| 2024-10-31 17:45 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 400.7 KB | ||
| 2024-10-31 17:45 |
Interim Report
Inside Information / News release on accounts, results
|
English | 464.4 KB | ||
| 2024-10-16 17:45 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 289.1 KB | ||
| 2024-10-16 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 223.1 KB | ||
| 2024-10-14 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 275.7 KB |
Automate Your Workflow. Get a real-time feed of all Acticor Biotech filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Acticor Biotech via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
